RNA结合蛋白人类抗原R在肝细胞癌中的研究进展

Research Progress of RNA-binding Protein Human Antigen R in Hepatocellular Carcinoma

肝细胞癌(HCC)具有发病率高、早期症状不明显、治疗手段局限、患者预后差等特点,因此寻找有效的早期诊断、监测、治疗HCC的方法迫在眉睫。RNA结合蛋白人类抗原R(HuR)作为一种重要的转录后调节因子,可通过调节相关靶信使RNA的稳定性、翻译、亚细胞定位和降解等生物过程参与肿瘤的发生发展。与邻近正常肝组织相比,HuR蛋白在HCC中持续高表达,并参与肝脏恶性转化相关基因的转录后调控。因此,HuR蛋白可作为HCC患者生存率较差的预测指标,深入研究HuR在HCC中的作用机制,可以为疾病的治疗提供新思路。

Hepatocellular carcinoma(HCC)is characterized by high incidence,inconspicuous early symptoms,limited treatment options,and poor prognosis.Therefore,it is very urgent to find effective methods for the early diagnosis,monitoring and treatment.RNA-binding protein human antigen R(HuR),as an important post-transcriptional regulator,participates in the occurrence and development of tumors by regulating biological processes such as stability,translation,subcellular localization and degradation of related targeted messenger RNA.Compared with adjacent normal liver tissues,HuR protein is continuously highly expressed in HCC and participates in the post-transcriptional regulation of liver malignant transformation related genes.Therefore,HuR protein can be used as a predictor of poor survival in HCC patients,and deeper study on the mechanism of action of HuR in HCC can provide new ideas for the treatment of the disease.